This website uses cookies, pixels, and similar technologies (“cookies”), some of which are provided by third parties, to enable website features and functionality; measure, analyze, and improve site performance; enhance user experience; record user interactions; and support our advertising and marketing. We and our third-party vendors may monitor, record, and access information and data, including device data, IP address and online identifiers, referring URLs and other browsing information, for these and similar purposes. By clicking “Accept all cookies,” you agree to such purposes. If you continue to browse our site without clicking “Accept all cookies,” or if you click “Reject all cookies,” only cookies necessary to operate and enable default website features and functionalities will be deployed. If you are visiting our Site in the U.S., by using this site or clicking “Accept all cookies,” “Reject all cookies,” or “Preferences,” you acknowledge and agree to our Privacy Policy, Cookie Policy, and Terms of Use.
Accept all cookiesReject all cookiesPreferences
mission
portfolioknowledge hub
about
careers

library

IQT News
/
No items found.

Microchip Biotechnologies, inc. Completes Series A Financing Round and Announces Development Agreement

August 30, 2006
Read the Paper

August 30, 2006

Microchip Biotechnologies, Inc., (MBI), today announced the completion of its Series A investment round. $4.5 million in total funding was secured, which includes equity and amounts based on further product development components. The round was co-led by In-Q-Tel, the independent strategic venture capital fund that identifies innovative technologies to support the missions of the Central Intelligence Agency (CIA) and the larger Intelligence Community, and RONA Syndicates LLC, a privately held Silicon Valley-based venture investment group. MBI is focused on commercializing products based on a patent-pending Microscale On-chip ValveTM (MOVTM) nanofluidic platform.

"The strategic investment by In-Q-Tel is a significant validation of MBI's MOVTM technology and our goal to leverage this platform in field-portable, integrated solutions," said Dr. Stevan Jovanovich, President and CEO of MBI. "We are delighted to secure the Series A funding that will enable us to bring our first microchip-based products to market."

The proceeds will accelerate the development efforts of MBI's first commercial products, develop portable forensics devices for DNA typing, and fund the critical infrastructure necessary for rapid prototyping and manufacturing of nanofluidic microchips.

"MBI is developing a breakthrough nanofluidic platform that may ultimately transform many integrated solutions that are integral to today's large laboratory-based systems," said Scott Yancey, President and CEO of In-Q-Tel. "MBI's technology also has the potential to create a tipping point in the development of field-portable integrated solutions and next-generation laboratory instrumentation, providing high value technology solutions for both federal and commercial markets."

‍About Microchip Biotechnologies

‍Microchip Biotechnologies, Inc. is an early-stage, privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analysis instrumentation for the genomics, biodefense, and forensics markets. These solutions are based on MBI's proprietary NanoBioProcessor‚Ñ¢ platform and associated ‚ÄòMicroscale-on-Chip Valves‚Ñ¢' (MOV‚Ñ¢) technology. More details can be found on the company's website: www.microchipbiotech.com.

‍About RONA Syndicates LLC

‍RONA Syndicates LLC is a privately held, Silicon Valley-based venture investment group. The RONA investment team also invested in ParAllele Biosciences, a genotyping company acquired by Affymetrix in 2005 and most recently in NextBio, a Life Sciences Bioinformatics company.

No items found.